The Biotech Trek: A Short History from 1993 to 2021 June 29, 2021
The Nasdaq Biotechnology Index (NBI) launched in 1993, when the industry was still in the midst of the original “biotech revolution.” Since then, its constituent basket has swelled from roughly 100 components to 274, reflecting the tremendous growth in the small cap space – the overwhelming majority of which has stemmed from IPOs on the Nasdaq Stock Exchange.
As the biotech industry enters a new phase of growth, it’s more important than ever for investors to consider their allocations toward the space.
In the upcoming webcast,
The Biotech Trek: A Short History from 1993 to 2021, Rene Reyna, Head of Thematic and Specialty Product Strategy ETFs and Indexed Strategies, Invesco; and Mark Marex, Research & Development Specialist, Nasdaq Global Indexes, will discuss the regulatory, scientific, and demographic factors driving today’s growth in biotech and why the Nasdaq Biotechnology Index’s methodology le
A Biotech ETF to Track Nasdaq s Industry-Setting Benchmark etftrends.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etftrends.com Daily Mail and Mail on Sunday newspapers.
All in the Genes: QQQ Offspring QQQJ Proves Success Breeds More Success
The
Invesco NASDAQ Next Gen 100 ETF (QQQJ) is part of this year’s bumper crop of new exchange traded funds. As a relative of the famed
Invesco QQQ Trust (NASDAQ: QQQ), the rookie ETF has a big legacy to live up to.
QQQJ, which is almost two months old, extends the QQQ ETF further by offering access to the “next 100” non-financial companies listed on the Nasdaq, outside of the NASDAQ-100 Index, offering a mid-cap alternative to the NASDAQ-100. In other words, QQQJ is a proving ground for companies that could eventually be added to the popular QQQ.